- Study: OTC ibuprofen as effective as Rx in treating post-operative pain after having tonsils removed
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Pfizer introduces a new faster-dissolving Advil tablet
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
IRVINE, Calif. Ista Pharmaceuticals has won approval from the Food and Drug Administration for a drug used to treat eye surgery patients.
The drug maker announced the approval of Bromday (bromfenac) ophthalmic solution as a once-daily eye drop for treating pain and inflammation in patients who have received cataract extraction surgery. The drug is a nonsteroidal anti-inflammatory drug, or NSAID, belonging to the same class as the common painkiller ibuprofen. The company plans to launch the drug at the end of this year.
“We believe the convenience of a once-daily eye drop will help with treatment compliance and benefit patients recovering from cataract surgery,” Ista president and CEO Vicente Anido said. “Bromday is an important addition to our growing prescription eye and allergy product portfolio.